Given the recent success of the novel anti-inflammatory strategy using anti-IL-1 antibody and others to modify systemic immune response in patients with acute coronary syndrome [45,46,47], further investigations of CCL4 may be interesting in terms of validating the anti-CCL4 strategy for potential clinical use in atherosclerotic diseases. This evidence concerns the gene CCL4 and acute coronary syndrome.